Literature DB >> 18403723

Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans.

Jacobien J Hoogerwerf1, Alex F de Vos, Paul Bresser, Jaring S van der Zee, Jennie M Pater, Anita de Boer, Michael Tanck, Daniel L Lundell, Chung Her-Jenh, Christian Draing, Sonja von Aulock, Tom van der Poll.   

Abstract

RATIONALE: Recognition of pathogen-associated molecular patterns by Toll-like receptors (TLRs) is considered to be important for an appropriate immune response against pathogens that enter the lower airways.
OBJECTIVES: We studied the effects of two different TLR agonists relevant for respiratory infections in the human lung: lipoteichoic acid (LTA; TLR2 agonist, component of gram-positive bacteria) and lipopolysaccharide (LPS; TLR4-agonist, component of gram-negative bacteria).
METHODS: Fifteen healthy subjects were given LPS or LTA: by bronchoscope, sterile saline was instilled into a lung segment followed by instillation of LTA or LPS into the contralateral lung. After 6 hours, a bronchoalveolar lavage was performed and inflammatory parameters were determined. Isolated RNA from purified alveolar macrophages was analyzed by multiplex ligation-dependent probe amplification. In addition, spontaneous cytokine release by alveolar macrophages was measured.
MEASUREMENTS AND MAIN RESULTS: Marked differences were detected between LTA- and LPS-induced lung inflammation. Whereas both elicited neutrophil recruitment, only LPS instillation was associated with activation of neutrophils (CD11b surface expression, degranulation product levels) and consistent rises of chemo-/cytokine levels. Moreover, LPS but not LTA activated alveolar macrophages, as reflected by enhanced expression of 10 different mRNAs encoding proinflammatory mediators and increased spontaneous cytokine release upon incubation ex vivo. Remarkably, only LTA induced C5a release.
CONCLUSIONS: This is the first study to report the in vivo effects of LTA in men and to compare inflammation induced by LTA and LPS in the human lung. Our data suggest that stimulation of TLR2 or TLR4 results in differential pulmonary inflammation, which may be of relevance for understanding pathogenic mechanisms at play during gram-positive and gram-negative respiratory tract infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403723     DOI: 10.1164/rccm.200708-1261OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  Bacterial lipoprotein TLR2 agonists broadly modulate endothelial function and coagulation pathways in vitro and in vivo.

Authors:  Hae-Sook Shin; Fengyun Xu; Aranya Bagchi; Elizabeth Herrup; Arun Prakash; Catherine Valentine; Hrishikesh Kulkarni; Kevin Wilhelmsen; Shaw Warren; Judith Hellman
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

Review 2.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

Review 3.  Immunopathogenesis of Staphylococcus aureus pulmonary infection.

Authors:  Dane Parker; Alice Prince
Journal:  Semin Immunopathol       Date:  2011-10-31       Impact factor: 9.623

4.  CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice.

Authors:  A S Gandhi; T Guo; P Shah; B Moorthy; D S-L Chow; M Hu; R Ghose
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Surfactant protein-D and exposure to bioaerosols in wastewater and garbage workers.

Authors:  R Daneshzadeh Tabrizi; A Bernard; A M Thommen; F De Winter; A Oppliger; S Hilfiker; A Tschopp; P Hotz
Journal:  Int Arch Occup Environ Health       Date:  2010-03-11       Impact factor: 3.015

6.  Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs.

Authors:  Martina Barrenschee; Dennis Lex; Stefan Uhlig
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

7.  Lipoteichoic acid from Staphylococcus aureus exacerbates respiratory disease in porcine respiratory coronavirus-infected pigs.

Authors:  Kalina Atanasova; Steven Van Gucht; Filip Barbé; Luc Duchateau; Kristien Van Reeth
Journal:  Vet J       Date:  2010-04-20       Impact factor: 2.688

Review 8.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

Review 9.  Pattern recognition receptor-dependent mechanisms of acute lung injury.

Authors:  Meng Xiang; Jie Fan
Journal:  Mol Med       Date:  2009-11-02       Impact factor: 6.354

10.  Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes.

Authors:  Esmeralda Juarez; Carlos Nuñez; Eduardo Sada; Jerrold J Ellner; Stephan K Schwander; Martha Torres
Journal:  Respir Res       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.